RT Journal Article
SR Electronic
T1 Deep Learning Approach to Parse Eligibility Criteria in Dietary Supplements Clinical Trials Following OMOP Common Data Model
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.16.20196022
DO 10.1101/2020.09.16.20196022
A1 Bompelli, Anusha
A1 Li, Jianfu
A1 Xu, Yiqi
A1 Wang, Nan
A1 Wang, Yanshan
A1 Adam, Terrence
A1 He, Zhe
A1 Zhang, Rui
YR 2020
UL http://medrxiv.org/content/early/2020/09/18/2020.09.16.20196022.abstract
AB Dietary supplements (DSs) have been widely used in the U.S. and evaluated in clinical trials as potential interventions for various diseases. However, many clinical trials face challenges in recruiting enough eligible patients in a timely fashion, causing delays or even early termination. Using electronic health records to find eligible patients who meet clinical trial eligibility criteria has been shown as a promising way to assess recruitment feasibility and accelerate the recruitment process. In this study, we analyzed the eligibility criteria of 100 randomly selected DS clinical trials and identified both computable and non-computable criteria. We mapped annotated entities to OMOP Common Data Model (CDM) with novel entities (e.g., DS). We also evaluated a deep learning model (Bi-LSTM-CRF) for extracting these entities on CLAMP platform, with an average F1 measure of 0.601. This study shows the feasibility of automatic parsing of the eligibility criteria following OMOP CDM for future cohort identification.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is partially supported by the National Center for Complementary and Integrative Health (NCCIH) and the Office of Dietary Supplements (ODS) under grant number R01AT009457 (Zhang); and the University of Minnesota Clinical and Translational Science Institute (CTSI), supported by the National Center for Advancing Translational Sciences under grant number UL1TR002494.This study was also partially supported by the National Institute on Aging (NIA) of NIH under Award Number R21AG061431; and the University of Florida CTSI, which is supported in part by the National Center for Advancing Translational Sciences under award number UL1TR001427. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We only used publicly available data from ClinicalTrials.gov. No patient data was used. IRB is not applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data pertaining to this article is available upon request.